A couple of weeks ago I wrote about a remarkable study, just published in the BMJ which had found that over half of the new cancer drugs released onto the market in a four year period by the EU drugs regulator had no good evidence that they were effective. In other words, there was also no evidence that their benefits outweighed their risk or that they were value for money.
A couple of weeks ago I wrote about a remarkable study, just published in the BMJ which had found that over half of the new cancer drugs released onto the market in a four year period by the EU drugs regulator had no good evidence that they were effective. In other words, there was also no evidence that their benefits outweighed their risk or that they were value for money.
WINNER: Guild of Health Writers 2016 Awards – Online Category. For "Keep statin supremo away from the missing side-effect data" | 19 Feb 2015
Jerome Burne/ HealthInsightUK.org –
Finalist in the MJA's new Blogger of the Year awards, was 'highly commended' by the judges in this hotly contested category.
Recent Comments